Gilead's Trodelvy Misses Main Goal In Breast Cancer Study But Shows Early Survival Trend

benzinga.com/news/health-care/25/11/48721099/gileads-trodelvy-misses-main-goal-in-breast-cancer-study-but-shows-early-survival-trend

Gilead Sciences Inc. (NASDAQ:GILD) announced on Friday data from the Phase 3 ASCENT-07 study of Trodelvy (sacituzumab govitecan-hziy) versus chemotherapy in HR+/HER2-negative metastatic breast cancer patients.
The trial included patients who received prior endocrine therapy and were…

This story appeared on benzinga.com, 2025-11-07 15:10:32.
The Entire Business World on a Single Page. Free to Use →